proxyvotesnow.com

Home › Companies › EDITAS MEDICINE INC. › 2024-2025

EDITAS MEDICINE INC. 2024-2025 Proxy Voting Records

Compiled from SEC Form N-PX filings and EDITAS MEDICINE INC.’s Form 8-K, filed 2025-06-02 (Item 5.07 on EDGAR). Page generated 04 October 2026.

  • 12Reported items
  • 239Asset managers
  • 1,412Fund votes
  • 2025-05-29Meeting date

Proxy season: 2023-2024 2024-2025 2025-2026

Explore EDITAS MEDICINE INC. in the interactive database Compare manager voting policies

Official 2024-2025 meeting results reported by EDITAS MEDICINE INC.

These tallies are EDITAS MEDICINE INC.’s own, as disclosed to the U.S. Securities and Exchange Commission on Form 8-K, filed 2025-06-02 (Item 5.07, “Submission of Matters to a Vote of Security Holders”). They cover every share voted at the meeting, not just the funds that file Form N-PX.

EDITAS MEDICINE INC. — official shareholder meeting results, meeting held 2025-05-29
Ballot itemForAgainst AbstainWithheldBroker non-votesOutcome
Elect Director: Jessica Hopfield, Ph.D. 21,212,129---- 5,317,35126,052,859 Majority: yes
Elect Director: David Scadden, M.D. 24,052,406---- 2,477,07426,052,859 Majority: yes
Proposal 2: The Company's stockholders approved, on an advisory basis, the compensation paid to its named executive officers. 16,066,73810,241,052221,690 --26,052,859 Passed
Proposal 3: The Company's stockholders approved, on an advisory basis, a frequency of one year for future advisory votes on the compensation paid to its named executive officers. 25,160,123--316,138 --26,052,859 Passed
Proposal 4: The Company's stockholders approved an amendment and restatement of the Company's 2015 Stock Incentive Plan. 20,101,5896,265,763162,128 --26,052,859 Passed
Proposal 5: The Company's stockholders adopted and approved an amendment to the Company's Restated Certificate of Incorporation to increase the number of authorized shares of the Company's capital stock from 200,000,000 to 395,000,000 and the number of authori 38,719,40913,205,693657,237 --0 Passed
Proposal 6: The Company's stockholders ratified the selection of Ernst & Young LLP as the Company's independent registered public accounting firm for the current fiscal year. 51,108,9701,162,233311,136 --0 Majority: yes

Source: EDITAS MEDICINE INC., Form 8-K, filed with the SEC on 2025-06-02 — read the filing on EDGAR.

How asset managers voted at the EDITAS MEDICINE INC. 2024-2025 meeting

Each item below shows how the 239 asset managers that disclosed a EDITAS MEDICINE INC. vote in their SEC Form N-PX filings actually voted. Share totals are the shares those managers' funds voted, summed across every fund they report. These are reported items, not a count of the ballot: fund filings describe one ballot item in different words. Two descriptions are shown as one item only on evidence — the same text (or one cut short of the other), the same director nominee, or a match to the same row of EDITAS MEDICINE INC.’s own Form 8-K tally — never because they merely read alike. A description that could not be joined that way is listed on its own, so one ballot item can appear more than once.

1. To approve, on an advisory basis, the frequency of future advisory votes on the compensation paid to the Company's named executive officers.

SECTION 14A SAY-ON-PAY VOTESCompany result: Passed

Combines 8 wordings of this item as funds reported it.

— Passed · no against or withheld count reported

EDITAS MEDICINE INC.’s own tally for this item (“Proposal 3: The Company's stockholders approved, on an advisory basis, a frequency of one year for future advisory votes on the compensation paid to its named executive officers.”): 25,160,123 for; no against or withheld count reported — passed, per its Form 8-K filed 2025-06-02 (Item 5.07).

The 224 asset managers below cast 90% of the shares they voted on this item FOR (280,143 for, 29,593 against).

ONE YEAR 66%1 YEAR 31%
FOR: 280,143 (1.2%)AGAINST: 29,593 (0.1%)ABSTAIN: 770 (0.0%)ONE YEAR: 14,969,855 (65.8%)1 YEAR: 7,026,824 (30.9%)THREE YEARS: 422,263 (1.9%)3 YEARS: 15,847 (0.1%)NOT VOTED: 13,731 (0.1%)1-YEAR: 534 (0.0%)1YEAR: 125 (0.0%)2 YEARS: 80 (0.0%)1: 50 (0.0%)
Largest asset managers voting on “To approve, on an advisory basis, the frequency of future advisory votes on the compensation paid to the Compa” at EDITAS MEDICINE INC., 2024-2025
Asset managerForAgainst AbstainWithheldVote
Vanguard00 00One Year
BlackRock00 001 Year
GEODE CAPITAL MANAGEMENT, LLC00 00One Year
Fidelity00 00One Year
Charles Schwab00 001 Year
State Street00 00One Year
Dimensional00 00Three Years
STIFEL NICOLAUS & CO INC \MO\00 00One Year
Northern Trust00 001 Year
UBS00 00One Year
SEI00 001 Year
KENNEDY CAPITAL MANAGEMENT LLC00 00One Year
DE Shaw00 00One Year
Renaissance00 00One Year
Goldman Sachs00 00One Year
Green Alpha Advisors, LLC203,6580 00For
Equitable00 00One Year
Global X00 001 Year
MARSHALL WACE, LLP00 001 Year
MELLON INVESTMENTS Corp00 00One Year
AQR00 00One Year
AllianceBernstein00 00One Year
Thrivent00 00One Year
Invesco00 00One Year
QUANTITATIVE MASTER SERIES LLC00 001 Year

Showing the 25 largest of 224 asset managers. See all 224 in the interactive database.

2. To approve, on an advisory basis, the compensation paid to the Company's named executive officers.

SECTION 14A SAY-ON-PAY VOTES

Combines 4 wordings of this item as funds reported it.

59% fund support · no official result

FOR 59%AGAINST 41%

The 223 asset managers below cast 59% of the shares they voted on this item FOR (13,366,766 for, 9,176,047 against).

FOR: 13,366,766 (59.3%)AGAINST: 9,176,047 (40.7%)ABSTAIN: 770 (0.0%)NOT VOTED: 13,731 (0.1%)
Largest asset managers voting on “To approve, on an advisory basis, the compensation paid to the Company's named executive officers.” at EDITAS MEDICINE INC., 2024-2025
Asset managerForAgainst AbstainWithheldVote
Vanguard7,116,85923,492 00For
BlackRock48,5773,998,226 00Against
GEODE CAPITAL MANAGEMENT, LLC1,856,7770 00For
Fidelity1,731,17017,500 00For
Charles Schwab01,369,779 00Against
State Street900,1465,261 00For
Dimensional0418,270 00Against
STIFEL NICOLAUS & CO INC \MO\0364,720 00Against
Northern Trust364,5670 00For
UBS0360,502 00Against
SEI350,5460 00For
KENNEDY CAPITAL MANAGEMENT LLC0307,144 00Against
DE Shaw0227,317 00Against
Renaissance0205,937 00Against
Goldman Sachs205,0750 00For
Equitable0147,999 00Against
Global X147,4100 00For
MARSHALL WACE, LLP144,3060 00For
MELLON INVESTMENTS Corp143,3420 00For
AQR0137,119 00Against
AllianceBernstein0133,630 00Against
Thrivent0120,652 00Against
Invesco0117,904 00Against
QUANTITATIVE MASTER SERIES LLC0114,842 00Against
Nuveen085,661 00Against

Showing the 25 largest of 223 asset managers. See all 223 in the interactive database.

3. TO APPROVE AN AMENDMENT AND RESTATEMENT OF THE COMPANY'S 2015 STOCK INCENTIVE PLAN.

COMPENSATIONCompany result: Passed

Combines 4 wordings of this item as funds reported it.

76% Passed · of votes cast

FOR 76%AGAINST 24%
FOR: 20,101,589AGAINST: 6,265,763

EDITAS MEDICINE INC.’s own tally for this item (“Proposal 4: The Company's stockholders approved an amendment and restatement of the Company's 2015 Stock Incentive Plan.”): 20,101,589 for, 6,265,763 against — passed, per its Form 8-K filed 2025-06-02 (Item 5.07). Of all 83,709,536 outstanding shares: 24% for, 7% against (31% of the company cast a for/against vote).

The 51 asset managers below cast 94% of the shares they voted on this item FOR (12,384,571 for, 782,945 against).

FOR 94%
FOR: 12,384,571 (94.1%)AGAINST: 782,945 (5.9%)
Largest asset managers voting on “TO APPROVE AN AMENDMENT AND RESTATEMENT OF THE COMPANY'S 2015 STOCK INCENTIVE PLAN.” at EDITAS MEDICINE INC., 2024-2025
Asset managerForAgainst AbstainWithheldVote
Vanguard6,934,7970 00For
BlackRock2,107,1810 00For
Fidelity1,705,97017,500 00For
Charles Schwab684,8830 00For
Dimensional0245,741 00Against
Goldman Sachs191,4510 00For
SEI175,0380 00For
Equitable14,369133,630 00Against
Global X147,4100 00For
QUANTITATIVE MASTER SERIES LLC114,8420 00For
Amplify ETF Trust075,674 00Against
Investment Managers Series Trust II71,5260 00For
Lincoln Financial61,9383,993 00For
Thrivent059,541 00Against
Pacific Life48,0740 00For
Bridge Builder Trust39,8500 00For
Northern Trust39,7980 00For
Invesco036,296 00Against
MASTER INVESTMENT PORTFOLIO34,5300 00For
Listed Funds Trust031,670 00Against
Voya024,546 00Against
ProShares022,932 00Against
John Hancock020,270 00Against
BRIDGEWAY FUNDS INC020,000 00Against
Allspring018,979 00Against

Showing the 25 largest of 51 asset managers. See all 51 in the interactive database.

4. TO ADOPT AND APPROVE AN AMENDMENT TO THE COMPANY'S RESTATED CERTIFICATE OF INCORPORATION TO INCREASE THE NUMBER OF AUTHORIZED SHARES OF THE COMPANY'S CAPITAL STOCK FROM 200,000,000 TO 395,000,000 AND THE NUMBER OF AUTHORIZED SHARES OF THE COMPANY'S COMMON STOCK FROM 195,000,000 TO 390,000,000.

CAPITAL STRUCTURECompany result: Passed

Combines 3 wordings of this item as funds reported it.

75% Passed · of votes cast

FOR 75%AGAINST 25%
FOR: 38,719,409AGAINST: 13,205,693

EDITAS MEDICINE INC.’s own tally for this item (“Proposal 5: The Company's stockholders adopted and approved an amendment to the Company's Restated Certificate of Incorporation to increase the number of authorized shares of the Company's capital stock from 200,000,000 ”): 38,719,409 for, 13,205,693 against — passed, per its Form 8-K filed 2025-06-02 (Item 5.07). Of all 83,709,536 outstanding shares: 46.3% for, 16% against (62% of the company cast a for/against vote).

The 48 asset managers below cast 79% of the shares they voted on this item FOR (10,369,088 for, 2,798,286 against).

FOR 79%AGAINST 21%
FOR: 10,369,088 (78.7%)AGAINST: 2,798,286 (21.3%)
Largest asset managers voting on “TO ADOPT AND APPROVE AN AMENDMENT TO THE COMPANY'S RESTATED CERTIFICATE OF INCORPORATION TO INCREASE THE NUMBE” at EDITAS MEDICINE INC., 2024-2025
Asset managerForAgainst AbstainWithheldVote
Vanguard6,934,7970 00For
BlackRock2,107,1810 00For
Fidelity17,5001,705,970 00Against
Charles Schwab0684,883 00Against
Dimensional245,7410 00For
Goldman Sachs191,4510 00For
SEI0175,038 00Against
Equitable147,9990 00For
Global X0147,410 00Against
QUANTITATIVE MASTER SERIES LLC114,8420 00For
Amplify ETF Trust075,674 00Against
Investment Managers Series Trust II71,5260 00For
Lincoln Financial65,9310 00For
Thrivent59,5410 00For
Pacific Life48,0740 00For
Bridge Builder Trust39,8500 00For
Northern Trust39,7980 00For
Invesco36,2960 00For
MASTER INVESTMENT PORTFOLIO34,5300 00For
Listed Funds Trust31,6700 00For
Voya24,5460 00For
ProShares22,9320 00For
John Hancock20,2700 00For
BRIDGEWAY FUNDS INC20,0000 00For
Allspring18,9790 00For

Showing the 25 largest of 48 asset managers. See all 48 in the interactive database.

5. TO RATIFY THE APPOINTMENT OF ERNST & YOUNG LLP AS THE COMPANY'S INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM FOR THE FISCAL YEAR ENDING DECEMBER 31, 2025.

AUDIT-RELATEDMajority of the votes cast: yes

Combines 2 wordings of this item as funds reported it.

98% Majority: yes · of votes cast

FOR 98%
FOR: 51,108,970AGAINST: 1,162,233

EDITAS MEDICINE INC.’s own tally for this item (“Proposal 6: The Company's stockholders ratified the selection of Ernst & Young LLP as the Company's independent registered public accounting firm for the current fiscal year.”): 51,108,970 for, 1,162,233 against, per its Form 8-K filed 2025-06-02 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item. Of all 83,709,536 outstanding shares: 61% for, 1% against (62% of the company cast a for/against vote).

The 47 asset managers below cast 99.4% of the shares they voted on this item FOR (13,090,754 for, 76,520 against).

FOR 99.4%
FOR: 13,090,754 (99.4%)AGAINST: 76,520 (0.6%)
Largest asset managers voting on “TO RATIFY THE APPOINTMENT OF ERNST & YOUNG LLP AS THE COMPANY'S INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM ” at EDITAS MEDICINE INC., 2024-2025
Asset managerForAgainst AbstainWithheldVote
Vanguard6,934,7970 00For
BlackRock2,107,1810 00For
Fidelity1,723,4700 00For
Charles Schwab684,8830 00For
Dimensional245,7410 00For
Goldman Sachs191,4510 00For
SEI175,0380 00For
Equitable147,9990 00For
Global X147,4100 00For
QUANTITATIVE MASTER SERIES LLC114,8420 00For
Amplify ETF Trust075,674 00Against
Investment Managers Series Trust II71,5260 00For
Lincoln Financial65,9310 00For
Thrivent59,5410 00For
Pacific Life48,0740 00For
Bridge Builder Trust39,8500 00For
Northern Trust39,7980 00For
Invesco36,2960 00For
MASTER INVESTMENT PORTFOLIO34,5300 00For
Listed Funds Trust31,6700 00For
Voya24,5460 00For
ProShares22,9320 00For
John Hancock20,2700 00For
BRIDGEWAY FUNDS INC20,0000 00For
Allspring18,9790 00For

Showing the 25 largest of 47 asset managers. See all 47 in the interactive database.

6. Election of two Class III Directors, each to serve until the 2028 annual meeting of stockholders: David T. Scadden, M.D.

DIRECTOR ELECTIONSMajority of the votes cast: yes

Combines 4 wordings of this item as funds reported it.

91% Majority: yes · of votes cast

FOR 91%9%
FOR: 24,052,406WITHHELD: 2,477,074

EDITAS MEDICINE INC.’s own tally for this item (“Elect Director: David Scadden, M.D.”): 24,052,406 for, 2,477,074 withheld, per its Form 8-K filed 2025-06-02 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item. Of all 83,709,536 outstanding shares: 29% for, 3% withheld (32% of the company cast a for/withheld vote).

The 45 asset managers below cast 100% of the shares they voted on this item FOR (12,579,309 for, 0 against).

FOR 96%
FOR: 12,579,309 (96.1%)ABSTAIN: 515,439 (3.9%)
Largest asset managers voting on “Election of two Class III Directors, each to serve until the 2028 annual meeting of stockholders: David T. Sca” at EDITAS MEDICINE INC., 2024-2025
Asset managerForAgainst AbstainWithheldVote
Vanguard6,934,7970 00For
BlackRock2,107,1810 00For
Fidelity1,723,4700 00For
Charles Schwab684,8830 00For
Dimensional00 245,7410Abstain
Goldman Sachs191,4510 00For
SEI175,0380 00For
Equitable14,3690 133,6300Abstain
Global X147,4100 00For
QUANTITATIVE MASTER SERIES LLC114,8420 00For
Amplify ETF Trust00 75,6740Abstain
Lincoln Financial61,9380 3,9930For
Thrivent59,5410 00For
Pacific Life48,0740 00For
Bridge Builder Trust39,8500 00For
Northern Trust00 39,7980Abstain
Invesco36,2960 00For
MASTER INVESTMENT PORTFOLIO34,5300 00For
Listed Funds Trust31,6700 00For
Voya24,5460 00For
ProShares22,9320 00For
John Hancock15,4230 4,8470For
BRIDGEWAY FUNDS INC20,0000 00For
Allspring18,9790 00For
Blackstone Alternative Investment Funds18,6000 00For

Showing the 25 largest of 45 asset managers. See all 45 in the interactive database.

7. Election of two Class III Directors, each to serve until the 2028 annual meeting of stockholders: Jessica Hopfield, Ph.D.

DIRECTOR ELECTIONSMajority of the votes cast: yes

Combines 4 wordings of this item as funds reported it.

80% Majority: yes · of votes cast

FOR 80%WITHHELD 20%
FOR: 21,212,129WITHHELD: 5,317,351

EDITAS MEDICINE INC.’s own tally for this item (“Elect Director: Jessica Hopfield, Ph.D.”): 21,212,129 for, 5,317,351 withheld, per its Form 8-K filed 2025-06-02 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item. Of all 83,709,536 outstanding shares: 25% for, 6% withheld (32% of the company cast a for/withheld vote).

The 45 asset managers below cast 100% of the shares they voted on this item FOR (12,124,544 for, 0 against).

FOR 93%7%
FOR: 12,124,544 (92.6%)ABSTAIN: 970,204 (7.4%)
Largest asset managers voting on “Election of two Class III Directors, each to serve until the 2028 annual meeting of stockholders: Jessica Hopf” at EDITAS MEDICINE INC., 2024-2025
Asset managerForAgainst AbstainWithheldVote
Vanguard6,934,7970 00For
BlackRock2,107,1810 00For
Fidelity1,705,9700 17,5000For
Charles Schwab684,8830 00For
Dimensional00 245,7410Abstain
Goldman Sachs00 191,4510Abstain
SEI175,0380 00For
Equitable14,3690 133,6300Abstain
Global X147,4100 00For
QUANTITATIVE MASTER SERIES LLC114,8420 00For
Amplify ETF Trust00 75,6740Abstain
Lincoln Financial61,9380 3,9930For
Thrivent00 59,5410Abstain
Pacific Life48,0740 00For
Bridge Builder Trust39,8500 00For
Northern Trust39,7980 00For
Invesco00 36,2960Abstain
MASTER INVESTMENT PORTFOLIO34,5300 00For
Listed Funds Trust00 31,6700Abstain
Voya00 24,5460Abstain
ProShares00 22,9320Abstain
John Hancock00 20,2700Abstain
BRIDGEWAY FUNDS INC00 20,0000Abstain
Allspring00 18,9790Abstain
Blackstone Alternative Investment Funds00 18,6000Abstain

Showing the 25 largest of 45 asset managers. See all 45 in the interactive database.

8. 14A Executive Compensation

SECTION 14A SAY-ON-PAY VOTES

Combines 2 wordings of this item as funds reported it.

97% fund support · no official result

FOR 97%

The 4 asset managers below cast 97% of the shares they voted on this item FOR (146,614 for, 5,000 against).

FOR: 146,614 (96.7%)AGAINST: 5,000 (3.3%)
Largest asset managers voting on “14A Executive Compensation” at EDITAS MEDICINE INC., 2024-2025
Asset managerForAgainst AbstainWithheldVote
Green Alpha Advisors, LLC146,3940 00For
Focus Partners Wealth1005,000 00Against
VOISARD ASSET MANAGEMENT GROUP, INC.1000 00For
Claret Asset Management Corp200 00For

9. Election of Directors

SECTION 14A SAY-ON-PAY VOTES

All nominees (reported as one line). These filers reported the election of directors as a single line covering every nominee. It is not attributed to any one director, and no share total is shown for it.

Combines 2 wordings of this item as funds reported it.

100% fund support · no official result

FOR 100%

The 2 asset managers below cast 100% of the shares they voted on this item FOR.

FOR: 100.0%
Largest asset managers voting on “Election of Directors” at EDITAS MEDICINE INC., 2024-2025
Asset managerForAgainst AbstainWithheldVote
Green Alpha Advisors, LLC235,5240 00For
VOISARD ASSET MANAGEMENT GROUP, INC.1000 00For

10. DIRECTOR

DIRECTOR ELECTIONS

1% fund support · no official result

AGAINST 99%

The 2 asset managers below cast 1% of the shares they voted on this item FOR (1,000 for, 71,526 against).

FOR: 1,000 (1.4%)AGAINST: 71,526 (98.6%)
Largest asset managers voting on “DIRECTOR” at EDITAS MEDICINE INC., 2024-2025
Asset managerForAgainst AbstainWithheldVote
Investment Managers Series Trust II071,526 00Against
BRANDYWINE OAK PRIVATE WEALTH LLC1,0000 00For

11. Advisory Vote on Say on Pay Frequency

SECTION 14A SAY-ON-PAY VOTESCompany result: Passed

— Passed · no against or withheld count reported

EDITAS MEDICINE INC.’s own tally for this item (“Proposal 3: The Company's stockholders approved, on an advisory basis, a frequency of one year for future advisory votes on the compensation paid to its named executive officers.”): 25,160,123 for; no against or withheld count reported — passed, per its Form 8-K filed 2025-06-02 (Item 5.07).

No shares were cast for or against this item by the managers below — every disclosed position was an abstention or was not voted.

ONE YEAR 100%
ONE YEAR: 735,020 (100.0%)
Largest asset managers voting on “Advisory Vote on Say on Pay Frequency” at EDITAS MEDICINE INC., 2024-2025
Asset managerForAgainst AbstainWithheldVote
JPMorgan00 00One Year
TD Waterhouse Canada Inc.00 00One Year

12. Advisory Vote to Ratify Named Executive Officers' Compensation

SECTION 14A SAY-ON-PAY VOTES

99.9% fund support · no official result

FOR 99.9%

The 2 asset managers below cast 99.9% of the shares they voted on this item FOR (734,520 for, 500 against).

FOR: 734,520 (99.9%)AGAINST: 500 (0.1%)
Largest asset managers voting on “Advisory Vote to Ratify Named Executive Officers' Compensation” at EDITAS MEDICINE INC., 2024-2025
Asset managerForAgainst AbstainWithheldVote
JPMorgan734,5200 00For
TD Waterhouse Canada Inc.0500 00Against

Largest EDITAS MEDICINE INC. shareholders voting in 2024-2025

Ranked by the number of EDITAS MEDICINE INC. shares each manager voted on the most widely held ballot item of the 2024-2025 meeting, shown as a share of the 83,709,536 shares outstanding at the time of that meeting.

Top EDITAS MEDICINE INC. shareholders by shares voted, 2024-2025
#Asset manager % of shares outstanding
1Vanguard 8.53%
2BlackRock 4.83%
3GEODE CAPITAL MANAGEMENT, LLC 2.22%
4Fidelity 2.09%
5Charles Schwab 1.65%
6State Street 1.08%
7Dimensional 0.50%
8STIFEL NICOLAUS & CO INC \MO\ 0.44%
9Northern Trust 0.44%
10UBS 0.43%

Reported EDITAS MEDICINE INC. ownership

Positions disclosed to the SEC on Schedules 13D and 13G, Form 13F and the company’s own proxy statement (DEF 14A).

EDITAS MEDICINE INC. beneficial owners on record for the 2024-2025 proxy season
Holder % outstanding Disclosure
Commodore Capital LP 19.17% 13G
TCG Crossover GP III, LLC 18.87% 13G
Vanguard Group 8.92% 13F
BlackRock 7.99% 13F
Morgan Stanley 3.18% 13F
Geode Capital 2.32% 13F
State Street 2.21% 13F
Dimensional Fund Advisors 1.92% 13F
Two Sigma 1.49% 13F
Renaissance Technologies 1.23% 13F

Percentages above are of 83,709,536 shares outstanding, as reported by EDITAS MEDICINE INC. on its Form 10-Q dated 2025-03-31 (see the filing on EDGAR). This is the count contemporaneous with the 2024-2025 meeting, so the percentages are the ones that were true then, not ones restated against today’s share count.

About this page

Every figure above is derived from filings made with the US Securities and Exchange Commission: Form N-PX, in which registered investment companies and institutional managers disclose how they voted every proxy, and Form 8-K Item 5.07, in which the company reports its own meeting results. Shares outstanding are taken from EDITAS MEDICINE INC.’s 10-Q dated 2025-03-31. This page is a static snapshot rebuilt weekly on 04 October 2026; a live search always shows the current data.

At EDITAS MEDICINE INC.'s shareholder meeting held 2025-05-29, in the 2024-2025 proxy season, 239 asset managers reported how they voted in their SEC Form N-PX filings, covering 1,412 separate fund positions. Their filings are grouped here into 12 reported items; because filers word the same ballot item differently, that can be more than the number of items on the ballot. On the most widely held item on that ballot — To approve, on an advisory basis, the frequency of future advisory votes on the compensation… — EDITAS MEDICINE INC. reported that the proposal passed. No complete for/against tally from that filing is on record here, so no support percentage is given for it. Source: EDITAS MEDICINE INC.'s Form 8-K, Item 5.07, filed with the U.S. Securities and Exchange Commission on 2025-06-02.

EDITAS MEDICINE INC. proxy season coverage: 2023-2024 · 2024-2025 (this page) · 2025-2026.